DPX-Survivac and Checkpoint Inhibitor in DLBCL

Clinical trial NCT03349450 · COMPLETED

Trial details

NCT number: NCT03349450
Sponsor: Sunnybrook Health Sciences Centre
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Adult Diffuse Large Cell Lymphoma Recurrent Adult Refractory Diffuse Large B-Cell Lymphoma

Start date: 2018-03-13
Primary completion: 2021-10-31
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.